Literature DB >> 28808896

Regadenoson use for stress myocardial perfusion imaging in advance chronic kidney disease and dialysis: Safe, effective, and efficient.

Ankur Gupta1, Navkaranbir S Bajaj2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28808896      PMCID： PMC5802370          DOI： 10.1007/s12350-017-1038-1

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN： 1071-3581            Impact factor:   5.952


× No keyword cloud information.
  16 in total

1.  Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function.

Authors:  Toufigh Gordi; Brent Blackburn; Hsiao Lieu
Journal:  J Clin Pharmacol       Date:  2007-07       Impact factor: 3.126

2.  2013 American Society of Nuclear Cardiology / MedAxiom Nuclear Survey.

Authors: 
Journal:  J Nucl Cardiol       Date:  2014-04       Impact factor: 5.952

3.  Influence of hemodialysis on regadenoson clearance in an in vitro hemodialysis model.

Authors:  Katherine N Gharibian; Venkatesh L Murthy; Bruce A Mueller
Journal:  J Nucl Cardiol       Date:  2016-09-15       Impact factor: 5.952

4.  Impact of a regimented aminophylline administration protocol on the burden of regadenoson-induced ischemia detected by SPECT myocardial perfusion imaging.

Authors:  Ibtihaj Fughhi; Tania Campagnoli; Amjad Ali; Rami Doukky
Journal:  J Nucl Cardiol       Date:  2016-05-27       Impact factor: 5.952

5.  Safety profile of adenosine stress perfusion imaging: results from the Adenoscan Multicenter Trial Registry.

Authors:  M D Cerqueira; M S Verani; M Schwaiger; J Heo; A S Iskandrian
Journal:  J Am Coll Cardiol       Date:  1994-02       Impact factor: 24.094

6.  Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial.

Authors:  Ami E Iskandrian; Timothy M Bateman; Luiz Belardinelli; Brent Blackburn; Manuel D Cerqueira; Robert C Hendel; Hsiao Lieu; John J Mahmarian; Ann Olmsted; S Richard Underwood; João Vitola; Whedy Wang
Journal:  J Nucl Cardiol       Date:  2007 Sep-Oct       Impact factor: 5.952

7.  Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results.

Authors:  Manuel D Cerqueira; Patricia Nguyen; Peter Staehr; S Richard Underwood; Ami E Iskandrian
Journal:  JACC Cardiovasc Imaging       Date:  2008-05

8.  Regadenoson provides perfusion results comparable to adenosine in heterogeneous patient populations: a quantitative analysis from the ADVANCE MPI trials.

Authors:  John J Mahmarian; Leif E Peterson; Jiaqiong Xu; Manuel D Cerqueira; Ami E Iskandrian; Timothy M Bateman; Gregory S Thomas; Faisal Nabi
Journal:  J Nucl Cardiol       Date:  2014-10-07       Impact factor: 5.952

9.  Safety of regadenoson in patients with end-stage renal disease.

Authors:  Wael Aljaroudi; Daniel Hermann; Fadi Hage; Jaekyeong Heo; Ami E Iskandrian
Journal:  Am J Cardiol       Date:  2009-11-18       Impact factor: 2.778

10.  A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease.

Authors:  Karthik Ananthasubramaniam; Robert Weiss; Bruce McNutt; Barbara Klauke; Kathleen Feaheny; Stan Bukofzer
Journal:  J Nucl Cardiol       Date:  2012-01-19       Impact factor: 5.952
View more
  4 in total

1.  Gender-related differences in side-effects and hemodynamic response to regadenoson in patients undergoing SPECT myocardial perfusion imaging.

Authors:  Athanasios Katsikis; Elena Kyrozi; Vasiliki Manira; Athanasios Theodorakos; Julia Malamitsi; Virginia Tsapaki; Ioannis Iakovou; Vasilios Voudris; Genovefa Kolovou; Maria Koutelou
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-14       Impact factor: 9.236

2.  Regadenoson versus dipyridamole: Evaluation of stress myocardial blood flow response on a CZT-SPECT camera.

Authors:  Quentin Brana; Frédérique Thibault; Maxime Courtehoux; Gilles Metrard; Maria Joao Ribeiro; Denis Angoulvant; Matthieu Bailly
Journal:  J Nucl Cardiol       Date:  2020-07-10       Impact factor: 5.952

3.  Safety and tolerability of regadenoson in comparison with adenosine stress cardiovascular magnetic resonance: Data from a multicentre prospective registry.

Authors:  Jose V Monmeneu Menadas; Maria P García Gonzalez; Maria P Lopez-Lereu; Laura Higueras Ortega; Alicia M Maceira Gonzalez
Journal:  Int J Cardiovasc Imaging       Date:  2021-07-31       Impact factor: 2.357

4.  Evaluating the use of pharmacological stress agents during single-photon emission computed tomography myocardial perfusion imaging tests after inadequate exercise stress test.

Authors:  Hongbo Yang; Elizabeth Faust; Emily Gao; Sakshi Sethi; Therese M Kitt; Rita M Kristy; James R Spalding; Yanqing Xu
Journal:  J Nucl Cardiol       Date:  2021-03-11       Impact factor: 3.872
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.